Family Lifestyles, Actions, and Risk Education Intervention: Version 2
| 适应症 | Melanoma, Child |
|---|---|
| 分期 | 不适用 |
| 申办方 | University of Utah |
| 状态 | 已完成 |
| 受试者人数 | 752 人 |
| 干预(药物) | FLARE Intervention |
| 开始日期 | 2020年4月7日 |
| 完成日期 | 2025年1月28日 |
| 结果公布日 | 2026年6月18日 |
摘要
The overall purpose of this study is to determine the efficacy of the Family Lifestyles, Actions, and Risk Education (FLARE) intervention in improving melanoma preventive behaviors. Parent-child dyads, consisting of survivors of melanoma and their children, will be randomly assigned to either receive the FLARE intervention or standard education. Once enrolled, each parent-child dyad will participate in this study for just over 1 year. Both conditions will receive three bi-weekly live intervention sessions (30 minutes per session) with an interventionist, and quarterly boosters via text or email.
Parent Report on Child Sunburn Occurrence Assessed Via Sun Habits Survey
| FLARE Intervention | 0.59 ± .851 score on a scale |
|---|---|
| Standard Education | 0.63 ± 0.932 score on a scale |
| FLARE Intervention | 0.42 ± 0.611 score on a scale |
| Standard Education | 0.56 ± 0.837 score on a scale |
| FLARE Intervention | 0.29 ± 0.522 score on a scale |
| Standard Education | 0.51 ± 0.849 score on a scale |
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration — National Cancer Institute (NCI)
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-I — National Cancer Institute (NCI)
- Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab — National Cancer Institute (NCI)
- Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With — Bristol-Myers Squibb
- Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Select — National Cancer Institute (NCI)
- Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, — National Cancer Institute (NCI)